NEOCUBES PHARMA
GenericsNEOCUBES PHARMA is a generic drug manufacturer focused on Cardiovascular, Respiratory.
NEOCUBES PHARMA's Key Drugs
NEOCUBES PHARMA's core commercial portfolio centers on AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
NEOCUBES PHARMA's Recent FDA Approvals
New NDA/BLA approvals for NEOCUBES PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
NEOCUBES PHARMA's Therapeutic Areas
NEOCUBES PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NEOCUBES PHARMA's Top Competitors
NEOCUBES PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NEOCUBES PHARMA Pipeline Snapshot
Active clinical trials for NEOCUBES PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-01-11
- Latest
- 2024-05-17
- Applications
- 2